Literature DB >> 15027856

Unraveling the active conformation of urotensin II.

Alfonso Carotenuto1, Paolo Grieco, Pietro Campiglia, Ettore Novellino, Paolo Rovero.   

Abstract

Urotensin II (U-II) is a disulfide-bridged undecapeptide recently identified as the ligand of an orphan G-protein-coupled receptor. Human U-II (H-Glu-Thr-Pro-Asp-cyclo[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH) has been described as the most potent vasoconstrictor compound identified to date. With the aim of elucidating the active conformation of hU-II, we have performed a spectroscopic analysis of hU-II minimal active fragment hU-II(4-11) in different environmental conditions. The analysis indicated that hU-II(4-11) was highly structured in the anisotropic membrane mimetic SDS solution, showing a type II' beta-turn structure, which is almost unprecedented for L-amino acid peptides. Micelle bound structure of hU-II(4-11) was then compared with those of four synthetic analogues recently synthesized in our lab, bearing modified Cys residues at position 5 and/or position 10 and characterized by different levels of agonist activity. The structures of the active compounds were found to be very similar to that of hU-II(4-11), while a barely active compound does not show any propensity to beta-turn formation. Furthermore, distances among putative pharmacophoric points in the structures of the active compounds obtained in SDS solution are in good agreement with those found in a recently described non-peptide agonist of the hU-II receptor. A type II' beta-turn structure was already found for the somatostatin analogue octreotide. On the basis of the similarity of the primary and 3D structures of U-II and somatostatin analogues and on the basis of the sequence homology between the GPR14/UT-II receptor and members of the somatostatin receptor family, a common evolutionary pathway for the signal transmission system activated by these peptide can be hypothesized.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15027856     DOI: 10.1021/jm0309912

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

Review 1.  Membrane catalysis of peptide-receptor binding.

Authors:  David N Langelaan; Jan K Rainey
Journal:  Biochem Cell Biol       Date:  2010-04       Impact factor: 3.626

2.  Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.

Authors:  Brian J Holleran; Marie-Eve Beaulieu; Christophe D Proulx; Pierre Lavigne; Emanuel Escher; Richard Leduc
Journal:  Biochem J       Date:  2007-02-15       Impact factor: 3.857

3.  Prediction of the three-dimensional structure for the rat urotensin II receptor, and comparison of the antagonist binding sites and binding selectivity between human and rat receptors from atomistic simulations.

Authors:  Soo-Kyung Kim; Youyong Li; Changmoon Park; Ravinder Abrol; William A Goddard
Journal:  ChemMedChem       Date:  2010-09-03       Impact factor: 3.466

4.  Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation.

Authors:  D Chatenet; M Létourneau; Q T Nguyen; N D Doan; J Dupuis; A Fournier
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

5.  Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures.

Authors:  Francesco Merlino; Salvatore Di Maro; Ali Munaim Yousif; Michele Caraglia; Paolo Grieco
Journal:  J Amino Acids       Date:  2013-02-25

6.  Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.

Authors:  David Chatenet; Thi-Tuyet M Nguyen; Myriam Létourneau; Alain Fournier
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-02       Impact factor: 5.555

Review 7.  Therapeutic potential of blockade of the urotensin II system in systemic hypertension.

Authors:  Henry Krum; Will Kemp
Journal:  Curr Hypertens Rep       Date:  2007-03       Impact factor: 4.592

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.